With a market cap of $98.8 billion, Marsh & McLennan Companies, Inc. (MRSH) is a global professional services firm headquartered in New York City. The company provides risk management, insurance and reinsurance brokerage, investment and retirement consulting, employee health and benefits solutions, and management consulting services to businesses, governments, and institutions across approximately 130 countries.
The insurance broker's shares have surpassed the broader market over the past 52 weeks. MRSH stock has surged 14.8% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 10.1%. Over the past six months, MRSH shares have gained 30.3%, compared to SPX’s marginal gain.
Moreover, shares of MRSH have outpaced the State Street Financial Select Sector SPDR ETF’s (XLF) 10.9% return over the past 52 weeks and 13.9% over the past six months.
On Nov. 10, Marsh agreed to acquire Wilshire, a global investment consulting, solutions, and analytics firm serving institutional investors and financial intermediaries. The transaction, expected to close in the first quarter of 2027, subject to regulatory approvals, customary closing conditions, and client consents, will expand Marsh's investment business into the advisor-led wealth segment and strengthen its capabilities in alternative investments, model portfolios, data, and analytics. The acquisition will also enhance its services for institutional clients, including retirement plans, endowments, and foundations. According to CEO John Doyle, the deal will combine Wilshire's investment expertise with Marsh's global reach and capabilities across public and private markets, enabling the company to offer more comprehensive investment solutions. Its shares popped 1.3% following the announcement.
Moreover, shares of Marsh rose 4.7% on Oct. 15 after the company reported strong third-quarter 2026 results, with revenue increasing 8% year over year to $6.86 billion and adjusted EPS climbing 10% to $2.03. Underlying revenue grew 5%, supported by growth in its People and Investments and Management Consulting businesses, as well as accelerating activity in Risk and Insurance Services.
For the fiscal year ending in December 2026, analysts expect Marsh & McLennan’s adjusted EPS to grow 7.6% year over year to $10.49. The company’s earnings surprise history is promising. It beat the consensus estimates in the last four quarters.
Among the 26 analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on nine “Strong Buy” ratings, 16 “Holds,” and one “Moderate Sell.”
The configuration is bearish than a month ago when the stock had eight “Strong Buy” suggestions.
On Nov. 3, BMO Capital upgraded Marsh from “Market Perform” to “Outperform,” setting a price target of $230. BMO noted that Marsh has one of the lowest organic growth hurdles among the six largest publicly traded insurance brokers for fiscal 2027. The firm also highlighted growth opportunities in Marsh's Europe, Middle East and Africa property and casualty business and management consulting operations.
While the stock currently trades above the mean price target of $208.59, the Street-high price target of $230 suggests a 9.6% potential upside.